Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mylan NV (NASDAQ:MYL)

37.51
Delayed Data
As of Oct 18
 -1.03 / -2.67%
Today’s Change
29.39
Today|||52-Week Range
45.87
-1.68%
Year-to-Date
Pricing Pressure, Competition Remain Headwinds for Pharma Stocks
Oct 18 / Zacks.com - Paid Partner Content
Teva Down as Mylan's Copaxone 40 mg Generic Arrives Early
Oct 05 / Zacks.com - Paid Partner Content
Allergan (AGN) Loses Restasis Patent Lawsuit, Shares Fall
Oct 17 / Zacks.com - Paid Partner Content
Company News For Oct 5, 2017
Oct 05 / Zacks.com - Paid Partner Content
Voyager Therapeutics (VYGR) Jumps: Stock Rises 7.8%
Oct 13 / Zacks.com - Paid Partner Content
Mylan (MYL) Surges: Stock Moves 16.2% Higher
Oct 05 / Zacks.com - Paid Partner Content
Mylan Gets Complete Response Letter For Biosimilar Neulasta
Oct 11 / Zacks.com - Paid Partner Content
US FDA approves generic competitor of Teva blockbuster drug
Oct 04 / FT.com - Paid Partner Content
Forget Teva (TEVA), Buy These 5 Drug Stocks Instead
Oct 09 / Zacks.com - Paid Partner Content
Allergan deal with Mohawk tribe casts patent shadow
Sep 27 / FT.com - Paid Partner Content
Pharma Stock Roundup: Mylan Up, Teva Down on Copaxone News, Lawmakers Question Allerg...
Oct 06 / Zacks.com - Paid Partner Content